---
title: "Alumis Inc. (ALMS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ALMS.US.md"
symbol: "ALMS.US"
name: "Alumis Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T06:02:25.268Z"
locales:
  - [en](https://longbridge.com/en/quote/ALMS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ALMS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ALMS.US.md)
---

# Alumis Inc. (ALMS.US)

## Company Overview

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.alumis.com](https://www.alumis.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: D (0.62)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 126 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -51.68% |  |
| Net Profit YoY | 30.85% |  |
| P/B Ratio | 4.83 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2737965642.83 |  |
| Revenue | 8402000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -64.57% | E |
| Profit Margin | -2825.70% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | -51.68% | E |
| Net Profit YoY | 30.85% | B |
| Total Assets YoY | 157.02% | A |
| Net Assets YoY | 236.88% | A |
| Cash Flow Margin | 158.48% | B |
| OCF YoY | -51.68% | E |
| Turnover | 0.02 | E |
| Gearing Ratio | 15.57% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Alumis Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-51.68%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "30.85%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.83",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2737965642.83",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "8402000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-64.57%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-2825.70%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-51.68%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "30.85%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "157.02%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "236.88%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "158.48%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-51.68%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "15.57%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -11.53 | 194/190 | - | - | - |
| PB | 4.83 | 149/190 | 8.72 | 1.98 | 0.99 |
| PS (TTM) | 325.87 | 157/190 | 133.53 | 30.25 | 14.96 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 82% |
| Overweight | 1 | 9% |
| Hold | 1 | 9% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 21.52 |
| Highest Target | 55.00 |
| Lowest Target | 25.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ALMS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ALMS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ALMS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ALMS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**